CR20190127A - Métodos para detectar aav - Google Patents

Métodos para detectar aav

Info

Publication number
CR20190127A
CR20190127A CR20190127A CR20190127A CR20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A CR 20190127 A CR20190127 A CR 20190127A
Authority
CR
Costa Rica
Prior art keywords
determining
particles
aav
heterogeneity
methods
Prior art date
Application number
CR20190127A
Other languages
English (en)
Inventor
Catherine R O´Riordan
Lin Liu
Xiaoying Jin
Kate Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59762045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CR20190127A publication Critical patent/CR20190127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente memoria se proporcionan métodos para determinar el serotipo de una partícula de virus y/o para determinar la heterogeneidad de una partícula de virus (p. ej., una partícula de AAV). En otras realizaciones, la invención proporciona métodos para determinar la heterogeneidad de partículas de AAV. En algunos aspectos, la invención proporciona partículas virales (p. ej., partículas de AAVr) con estabilidad mejorada y/o eficiencia de la transducción mejorada mediante el incremento de la acetilación y/o desamidación de las proteínas de la cápsideProvided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins.
CR20190127A 2016-08-15 2017-08-14 Métodos para detectar aav CR20190127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375314P 2016-08-15 2016-08-15
PCT/US2017/046814 WO2018035059A1 (en) 2016-08-15 2017-08-14 Methods for detecting aav

Publications (1)

Publication Number Publication Date
CR20190127A true CR20190127A (es) 2019-06-25

Family

ID=59762045

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190127A CR20190127A (es) 2016-08-15 2017-08-14 Métodos para detectar aav

Country Status (23)

Country Link
US (5) US11698377B2 (es)
EP (2) EP3497207B1 (es)
JP (3) JP7021191B2 (es)
KR (5) KR102922101B1 (es)
CN (2) CN110168080B (es)
AU (2) AU2017312951B2 (es)
CA (1) CA3033856A1 (es)
CL (2) CL2019000392A1 (es)
CR (1) CR20190127A (es)
CY (1) CY1124364T1 (es)
DK (1) DK3497207T3 (es)
ES (1) ES2863674T3 (es)
HU (1) HUE053747T2 (es)
IL (3) IL264819B2 (es)
MA (1) MA55748A (es)
MX (2) MX2019001938A (es)
NZ (3) NZ751711A (es)
PH (1) PH12019500316A1 (es)
SG (2) SG10201913002QA (es)
TN (1) TN2019000047A1 (es)
TW (2) TW202309068A (es)
WO (1) WO2018035059A1 (es)
ZA (2) ZA201900945B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
CA3033856A1 (en) 2016-08-15 2018-02-22 Genzyme Corporation Methods for detecting aav
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
IL276859B2 (en) * 2018-02-27 2025-12-01 Univ Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3768695A4 (en) * 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
EP3762500A1 (en) * 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
EP4509831A3 (en) * 2018-07-27 2025-03-19 Waters Technologies Corporation Liquid chromatography/mass spectrometry methods for the analysis of polar molecules
WO2020041498A1 (en) * 2018-08-21 2020-02-27 Massachusetts Eye And Ear Infirmary Compositions and methods for modulating transduction efficiency of adeno-associated viruses
IL282411B2 (en) * 2018-10-25 2025-09-01 Regeneron Pharma Methods for analyzing viral capsid protein composition
FI3953483T3 (fi) * 2019-04-11 2023-11-30 Regenxbio Inc Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
US11841352B2 (en) * 2019-07-31 2023-12-12 Thermo Finnigan Llc Determination and correction of retention time and mass/charge shifts in LC-MS experiments
CN114902051B (zh) * 2020-01-03 2026-04-17 萨勒普塔医疗公司 用于分析aav衣壳蛋白的方法
EP4097121A1 (en) 2020-01-29 2022-12-07 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CN111517359B (zh) * 2020-04-23 2021-08-20 江南大学 一种手性硫化铜超粒子的合成方法
RU2748540C1 (ru) * 2021-02-08 2021-05-26 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ детектирования вируса SARS-CoV-2 методом масс-спектрометрии
WO2022175728A1 (en) * 2021-02-19 2022-08-25 Waters Technologies Corporation Methods for peptide mapping of adeno-associated virus (aav) proteins
US20240382966A1 (en) * 2021-04-20 2024-11-21 Universal Bio-Sampling Inc. Specimen retention card and specimen inspection method using same
AU2022309726A1 (en) * 2021-07-12 2024-01-25 Regeneron Pharmaceuticals, Inc. Liquid chromatography assay for determining aav capsid ratio
TW202321691A (zh) * 2021-07-12 2023-06-01 美商再生元醫藥公司 用於分析病毒粒子之線上原生質譜方法
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
JPWO2023132338A1 (es) * 2022-01-06 2023-07-13
US20250110119A1 (en) * 2023-03-03 2025-04-03 Sartorius Bioanalytical Instruments, Inc. Methods for quantitating viral capsids
WO2024263520A1 (en) * 2023-06-19 2024-12-26 Regeneron Pharmaceuticals, Inc. Host cell protein analysis for adeno-associated virus (aav)-based gene therapy
WO2025101795A1 (en) * 2023-11-08 2025-05-15 Oxford Biomedica (Us) Llc Deamidation depleted adeno-associated virus product

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
SI1496944T1 (sl) 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
US20040172200A1 (en) * 2002-11-22 2004-09-02 Kearney Paul Edward Constellation mapping and uses thereof
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2311966A3 (en) * 2005-10-20 2012-09-05 Amsterdam Molecular Therapeutics (AMT) B.V. Improved AAV vectors produced in insect cells
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20110275529A1 (en) 2008-09-19 2011-11-10 Charite Universitatsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
KR20180000341A (ko) 2009-06-16 2018-01-02 젠자임 코포레이션 재조합 ａａｖ 벡터에 대한 개선된 정제 방법
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
WO2012031245A1 (en) * 2010-09-03 2012-03-08 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
NZ701693A (en) * 2012-04-18 2017-02-24 The Children’S Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
US20140017716A1 (en) * 2012-07-11 2014-01-16 Siscapa Assay Technologies, Inc. Proteolytic digestion kit with dried reagents
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
CA2942289C (en) 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
CA3033856A1 (en) 2016-08-15 2018-02-22 Genzyme Corporation Methods for detecting aav

Also Published As

Publication number Publication date
US20210041451A1 (en) 2021-02-11
KR102538037B1 (ko) 2023-05-30
US11698377B2 (en) 2023-07-11
NZ751711A (en) 2025-11-28
MA55748A (fr) 2022-03-02
AU2017312951A1 (en) 2019-04-04
US12298313B1 (en) 2025-05-13
HUE053747T2 (hu) 2021-07-28
BR112019002934A2 (pt) 2019-05-14
EP3497207B1 (en) 2021-01-06
US12123880B2 (en) 2024-10-22
IL264819B2 (en) 2024-10-01
NZ791267A (en) 2025-11-28
SG11201901221YA (en) 2019-03-28
TW202309068A (zh) 2023-03-01
CN110168080B (zh) 2024-05-31
US20250147042A1 (en) 2025-05-08
KR20240172773A (ko) 2024-12-10
ZA202101002B (en) 2024-07-31
US20250027951A1 (en) 2025-01-23
IL312792A (en) 2024-07-01
KR102922101B1 (ko) 2026-02-03
AU2024200349A1 (en) 2024-02-08
US20240044910A1 (en) 2024-02-08
KR20230078834A (ko) 2023-06-02
IL264819B1 (en) 2024-06-01
CL2019000392A1 (es) 2019-05-10
ES2863674T3 (es) 2021-10-11
WO2018035059A9 (en) 2019-03-14
AU2017312951B2 (en) 2024-02-08
ZA201900945B (en) 2021-06-30
KR102738219B1 (ko) 2024-12-05
JP2024023460A (ja) 2024-02-21
JP2022064980A (ja) 2022-04-26
KR20260036296A (ko) 2026-03-16
WO2018035059A1 (en) 2018-02-22
SG10201913002QA (en) 2020-03-30
EP3851449A1 (en) 2021-07-21
KR20190039253A (ko) 2019-04-10
RU2019107207A3 (es) 2021-04-29
CL2019002912A1 (es) 2020-03-06
JP7021191B2 (ja) 2022-02-16
KR102425289B1 (ko) 2022-07-27
TN2019000047A1 (en) 2020-07-15
JP2019533803A (ja) 2019-11-21
CY1124364T1 (el) 2022-07-22
TW201825898A (zh) 2018-07-16
NZ791263A (en) 2025-11-28
CN118688363A (zh) 2024-09-24
MX2019001938A (es) 2019-07-04
PH12019500316A1 (en) 2019-08-05
IL264819A (es) 2019-04-30
IL323969A (en) 2025-12-01
TWI781953B (zh) 2022-11-01
CN110168080A (zh) 2019-08-23
IL312792B2 (en) 2026-03-01
EP3497207A1 (en) 2019-06-19
DK3497207T3 (da) 2021-03-22
IL312792B1 (en) 2025-11-01
RU2019107207A (ru) 2020-09-15
MX2023009081A (es) 2023-08-08
US20250138024A1 (en) 2025-05-01
KR20220107327A (ko) 2022-08-02
CA3033856A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
CR20190127A (es) Métodos para detectar aav
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX388331B (es) Variantes de virus adenoasociado y métodos de uso de estas
WO2017066764A3 (en) Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
UY36522A (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
EP3790567A4 (en) LIVER-SPECIFIC TROPISM FROM ADENO-ASSOCIATED VIRUSES
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
EP3575398A4 (en) ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
IL292625A (en) Viruses with modified capsid proteins
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
BR112018071180A2 (pt) métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
MX2016010649A (es) Vector de virus adeno-asociado.
EP3347460A4 (en) MODIFIED ONCOLYTIC VACCINIA VIRUSES WITH CYTOKIN AND CAR-BOXY-REFERENCE EXPRESSION AND METHOD OF USE THEREOF
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
IL282411A (en) Methods for analysis of viral capsid protein composition
MX383506B (es) Parvovirus porcino.
MX378905B (es) Pestivirus.
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
EA201990955A1 (ru) Разработка капсидов aav
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
HK40009350A (en) Novel adeno-associated virus capsid proteins
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7